An Open-Label, Proof of Concept Study to Assess the Safety, Pharmacokinetics and Pharmacodynamics of MRG-001 in Patients With Amyotrophic Lateral Sclerosis
Latest Information Update: 26 Aug 2024
At a glance
- Drugs MRG-001 (Primary)
- Indications Amyotrophic lateral sclerosis
- Focus Adverse reactions; Proof of concept
- Sponsors MedRegen
Most Recent Events
- 23 Aug 2024 Planned End Date changed from 1 Dec 2024 to 1 Mar 2026.
- 23 Aug 2024 Planned primary completion date changed from 1 Nov 2024 to 1 Jan 2026.
- 23 Aug 2024 Planned initiation date changed from 1 Jul 2024 to 1 Jul 2025.